* Astria Therapeutics Inc ATXS.OQ reported a quarterly
adjusted
loss of 43 cents per share for the quarter ended in January,
higher than the same quarter last year, when the company
reported EPS of -45 cents. The mean expectation of six analysts
for the quarter was for a loss of 38 cents per share. Wall
Street expected results to range from -42 cents to -35 cents per
share.
* Reported revenue was zero; analysts expected zero.
* Astria Therapeutics Inc's reported EPS for the quarter was
a
loss of 43 cents.
* The company reported a quarterly loss of $24.17 million.
* Astria Therapeutics Inc shares had risen by 4.0% this
quarter and gained 23.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 3.3%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is "buy."
Wall Street's median 12-month price target for Astria
Therapeutics Inc is $25.50
This summary was machine generated from LSEG data August 13 at
04:31 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.38 -0.43 Missed
Mar. 31 2024 -0.36 -0.38 Missed
Dec. 31 2023 -0.78 -0.94 Missed
Sep. 30 2023 -0.49 -0.63 Missed